person · Reporting owner

Greenleaf Peter

Disclosed activity across 9 companies

Tapewire entity: 31647
SEC CIK: 0001363683

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Aurinia Pharmaceuticals Inc.AUPH · Entity 4463	Director · Chief Executive Officer	February 27, 2026	March 03, 2026
Avalo Therapeutics, Inc.CERC · Entity 4936	Director	August 07, 2019	October 03, 2019
KIORA PHARMACEUTICALS INCEYEG · Entity 7940	Director	February 01, 2019	February 05, 2019
Pelthos Therapeutics Inc.PTHS · Entity 6798	Director	October 02, 2026	October 06, 2026
SYNLOGIC, INC.MIRN · Entity 7801	Director	June 29, 2016	September 06, 2016
Savara IncMSTX · Entity 4900	Director	January 20, 2017	January 23, 2017

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Aurinia Pharmaceuticals Inc.

Report date February 27, 2026 · Filed March 03, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,840,379	Ending reported balance After 2026-03-02 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-02-27 · Grant · Acquired 196,403 · Balance 1,941,269 F1: Each performance right represents a contingent right to receive one common share of the Issuer. The performance rights vest in four tranches upon the Issuer's common shares achieving four progressively higher target prices, with respective one year retention periods per tranche achievement. Row 2 · 2026-03-02 · Tax withholding · Disposed 100,890 · Balance 1,840,379 F2: Represents shares withheld to satisfy tax withholding obligations upon the vesting of restricted stock units.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.97 · Expires 2036-02-27	Direct	328,424	Reported balance After 2026-02-27 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-02-27 · Grant · Acquired 328,424 · Balance 328,424 F3: One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter.

Filing footnotes · ownership attribution and instrument terms

F1: Each performance right represents a contingent right to receive one common share of the Issuer. The performance rights vest in four tranches upon the Issuer's common shares achieving four progressively higher target prices, with respective one year retention periods per tranche achievement.

F2: Represents shares withheld to satisfy tax withholding obligations upon the vesting of restricted stock units.

F3: One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter.

Avalo Therapeutics, Inc.

Report date August 07, 2019 · Filed October 03, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.93 · Expires 2029-08-07	Direct	25,000	Reported balance After 2019-08-07 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2019-08-07 · Grant · Acquired 25,000 · Balance 25,000 F1: The stock option will vest in full on August 7, 2020, subject to the Reporting Person's continued service on such vesting date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.80 · Expires 2027-05-12	Direct	16,714	Reported balance Holding disclosure · report date 2019-08-07 · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · Balance 16,714 F3: The stock option will vest in three substantially equal annual installments on May 11, 2018, 2019 and 2020, subject to the Reporting Person's continued service on each such vesting date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.57 · Expires 2027-06-30	Direct	8,357	Reported balance Holding disclosure · report date 2019-08-07 · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · Balance 8,357 F2: The stock option is fully vested.
Common StockSEC Table I · non-derivative	Direct	112,500	Reported balance Holding disclosure · report date 2019-08-07 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 112,500
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.24 · Expires 2028-03-27	Direct	135,417	Reported balance Holding disclosure · report date 2019-08-07 · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · Balance 135,417 F2: The stock option is fully vested.

Filing footnotes · ownership attribution and instrument terms

F1: The stock option will vest in full on August 7, 2020, subject to the Reporting Person's continued service on such vesting date.

F2: The stock option is fully vested.

F3: The stock option will vest in three substantially equal annual installments on May 11, 2018, 2019 and 2020, subject to the Reporting Person's continued service on each such vesting date.

KIORA PHARMACEUTICALS INC

Report date February 01, 2019 · Filed February 05, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.48 · Expires 2029-02-01	Direct	50,000	Reported balance After 2019-02-01 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2019-02-01 · Grant · Acquired 50,000 · Balance 50,000 F1: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to 100% of the shares underlying the Option on February 1, 2020.

Filing footnotes · ownership attribution and instrument terms

F1: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to 100% of the shares underlying the Option on February 1, 2020.

Pelthos Therapeutics Inc.

Report date October 02, 2026 · Filed October 06, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	23,087	Reported balance After 2026-10-02 transaction · row 1 1 source row Row 1 · 2026-10-02 · Sale · Disposed 797 · Balance 23,087 F1: This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer.

Filing footnotes · ownership attribution and instrument terms

F1: This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer.

SYNLOGIC, INC.

Report date June 29, 2016 · Filed September 06, 2016

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.74 · Expires 2026-06-29	Direct	10,000	Reported balance After 2016-06-29 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2016-06-29 · Grant · Acquired 10,000 · Balance 10,000 F1: The option vests and become exercisable in full on the earlier of (A) June 29, 2017 or (B) immediately prior to the next annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests and become exercisable in full on the earlier of (A) June 29, 2017 or (B) immediately prior to the next annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date.

Savara Inc

Report date January 20, 2017 · Filed January 23, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	45,535	Reported balance After 2017-01-20 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2017-01-20 · Grant · Acquired 45,535 · Balance 45,535 F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2: The restricted stock units vest in full upon consummation of the merger transaction contemplated by the Agreement and Plan of Merger, dated January 6, 2017, by and among the issuer, Savara Inc., and Victoria Merger Corp. (provided such event occurs on or before July 6, 2017).

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

F2: The restricted stock units vest in full upon consummation of the merger transaction contemplated by the Agreement and Plan of Merger, dated January 6, 2017, by and among the issuer, Savara Inc., and Victoria Merger Corp. (provided such event occurs on or before July 6, 2017).

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ANTARES PHARMA, INC.

Report date May 24, 2022 · Filed May 26, 2022

Section 16 reporting ended · disclosed 2022-05-26. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2022-05-24 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2022-05-24 · Disposition to issuer · Disposed 30,220 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 12, 2022, by and among the Issuer, Antares Pharma, Inc., a Delaware corporation (the "Company"), Halozyme Therapeutics, Inc., a Delaware corporation ("Parent"), and Atlas Merger Sub, Inc., a Delaware corporation ("Purchaser") and a wholly owned subsidiary of Parent, to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.01 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of May 24, 2022 (the "Effective Time"). F2: (Continued from Footnote 1) At the Effective Time, each Share outstanding immediately prior to the Effective Time (other than Excluded Shares) was converted into the right to receive $5.60 in cash, without interest (the "Merger Consideration") and subject to any withholding of taxes required by applicable legal requirements, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled.
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2022-05-24 transaction · row 2 Account or security details depend on footnotes; rows are not merged. 1 source row Row 2 · 2022-05-24 · Disposition to issuer · Disposed 49,425 · Balance 0 F3: Each Company restricted stock unit ("Company RSU") means any restricted stock unit granted under the Company Equity Plan. At the Effective Time, each Company RSU that was outstanding immediately prior to the Effective Time was cancelled at the Effective Time and converted into the right to receive a cash payment equal to the product of (i) the number of Shares issuable in settlement of the Company RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration. F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 12, 2022, by and among the Issuer, Antares Pharma, Inc., a Delaware corporation (the "Company"), Halozyme Therapeutics, Inc., a Delaware corporation ("Parent"), and Atlas Merger Sub, Inc., a Delaware corporation ("Purchaser") and a wholly owned subsidiary of Parent, to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.01 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of May 24, 2022 (the "Effective Time"). F2: (Continued from Footnote 1) At the Effective Time, each Share outstanding immediately prior to the Effective Time (other than Excluded Shares) was converted into the right to receive $5.60 in cash, without interest (the "Merger Consideration") and subject to any withholding of taxes required by applicable legal requirements, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.11	Direct	Reported balance After 2022-05-24 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2022-05-24 · Disposition to issuer · Disposed 20,000 · Balance 0 F4: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.92	Direct	Reported balance After 2022-05-24 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2022-05-24 · Disposition to issuer · Disposed 46,729 · Balance 0 F4: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.73	Direct	Reported balance After 2022-05-24 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2022-05-24 · Disposition to issuer · Disposed 58,246 · Balance 0 F4: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.42	Direct	Reported balance After 2022-05-24 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2022-05-24 · Disposition to issuer · Disposed 48,542 · Balance 0 F4: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 12, 2022, by and among the Issuer, Antares Pharma, Inc., a Delaware corporation (the "Company"), Halozyme Therapeutics, Inc., a Delaware corporation ("Parent"), and Atlas Merger Sub, Inc., a Delaware corporation ("Purchaser") and a wholly owned subsidiary of Parent, to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.01 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of May 24, 2022 (the "Effective Time").

F2: (Continued from Footnote 1) At the Effective Time, each Share outstanding immediately prior to the Effective Time (other than Excluded Shares) was converted into the right to receive $5.60 in cash, without interest (the "Merger Consideration") and subject to any withholding of taxes required by applicable legal requirements, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled.

F3: Each Company restricted stock unit ("Company RSU") means any restricted stock unit granted under the Company Equity Plan. At the Effective Time, each Company RSU that was outstanding immediately prior to the Effective Time was cancelled at the Effective Time and converted into the right to receive a cash payment equal to the product of (i) the number of Shares issuable in settlement of the Company RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration.

F4: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option.

BIODELIVERY SCIENCES INTERNATIONAL INC

Report date March 22, 2022 · Filed March 22, 2022

Section 16 reporting ended · disclosed 2022-03-22. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2022-03-22 transaction · row 1 1 source row Row 1 · 2022-03-22 · Other · Disposed 105,034 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of February 14, 2022, by and among the Issuer, Collegium Pharmaceutical, Inc., ("Parent"), and Bristol Acquisition Company Inc., a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of Issuer, $0.001 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of March 22, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $5.60 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2022-03-22 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-03-22 · Disposition to issuer · Disposed 27,746 · Balance 0 F2: Each restricted stock unit ("RSU") represents the contingent right to receive one Share. F3: Each Issuer RSUs that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the Merger Consideration.
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.93	Direct	Reported balance After 2022-03-22 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2022-03-22 · Disposition to issuer · Disposed 64,164 · Balance 0 F4: Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.66	Direct	Reported balance After 2022-03-22 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2022-03-22 · Disposition to issuer · Disposed 114,347 · Balance 0 F4: Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of February 14, 2022, by and among the Issuer, Collegium Pharmaceutical, Inc., ("Parent"), and Bristol Acquisition Company Inc., a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of Issuer, $0.001 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of March 22, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $5.60 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes.

F2: Each restricted stock unit ("RSU") represents the contingent right to receive one Share.

F3: Each Issuer RSUs that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the Merger Consideration.

F4: Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

Sucampo Pharmaceuticals, Inc.

Report date February 13, 2018 · Filed February 13, 2018

Section 16 reporting ended · disclosed 2018-02-13. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common Stock, Class ASEC Table I · non-derivative	Direct	Reported balance After 2018-02-13 transaction · row 1 1 source row Row 1 · 2018-02-13 · Disposition to issuer · Disposed 129,729 · Balance 0 F1: This common stock was purchased for $18.00 per share share in cash, subject to any required withholding of taxes and without interest, upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to that certain Agreement and Plan of Merger by and among Mallinckrodt plc, Sun Acquisition Co. and Sucampo Pharmaceuticals, Inc. dated December 23, 2017 (the "Merger Agreement"). The common stock consisted of both common stock and restricted stock units that were accelerated as a result of the Merger Agreement.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.49 · Expires 2024-03-03	Direct	Reported balance After 2018-02-13 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2018-02-13 · Disposition to issuer · Disposed 600,000 · Balance 0 F2: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.90 · Expires 2024-07-31	Direct	Reported balance After 2018-02-13 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2018-02-13 · Disposition to issuer · Disposed 200,000 · Balance 0 F2: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.82 · Expires 2025-03-04	Direct	Reported balance After 2018-02-13 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2018-02-13 · Disposition to issuer · Disposed 210,000 · Balance 0 F2: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.80 · Expires 2026-03-02	Direct	Reported balance After 2018-02-13 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2018-02-13 · Disposition to issuer · Disposed 420,000 · Balance 0 F2: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.85 · Expires 2027-03-02	Direct	Reported balance After 2018-02-13 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2018-02-13 · Disposition to issuer · Disposed 237,000 · Balance 0 F2: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement.

Filing footnotes · ownership attribution and instrument terms

F1: This common stock was purchased for $18.00 per share share in cash, subject to any required withholding of taxes and without interest, upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to that certain Agreement and Plan of Merger by and among Mallinckrodt plc, Sun Acquisition Co. and Sucampo Pharmaceuticals, Inc. dated December 23, 2017 (the "Merger Agreement"). The common stock consisted of both common stock and restricted stock units that were accelerated as a result of the Merger Agreement.

F2: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 11, 2020 Filed Jun 15, 2020 19:02 UTC	ANTARES PHARMA, INC. ATRS · Entity 126887	GrantStock Option (right to buy) · Derivative	58,246	$0.00 Strike: $2.73	$0.00	Disclosure SEC source: 0001209191-20-036771 · doc4.xml · derivative · entry 2 Greenleaf Peter · CIK 0001363683 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,246 Underlying: Common Stock · 58,246 shares Expires 2030-06-11 F2 · shares: Represents grant of options to purchase shares of common stock, par value $0.01 per share, issued under the Antares Pharma, Inc. Equity Compensation Plan. F3 · derivative.exercise_date: The options vest and become exercisable one year from the grant date. Read SEC document
June 11, 2020 Filed Jun 15, 2020 19:02 UTC	ANTARES PHARMA, INC. ATRS · Entity 126887	GrantCommon Stock	30,220	$2.73	$82,500.60	Disclosure SEC source: 0001209191-20-036771 · doc4.xml · nonDerivative · entry 1 Greenleaf Peter · CIK 0001363683 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,193 F1 · shares: Represents grant of restricted stock units made under the Antares Pharma, Inc. Equity Compensation Plan. The shares vest one year from the grant date. Read SEC document
August 13, 2019 Filed Aug 15, 2019 16:25 UTC	BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876	Exercise / conversionRestricted Stock Units · Derivative	21,144	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001103021-19-000006 · wf-form4_156590070881930.xml · derivative · entry 2 Greenleaf Peter · CIK 0001363683 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,500 Underlying: Common Stock · 21,144 shares Expires 2022-08-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units ("RSUs") granted to the Reporting Person on August 1, 2018 under the Issuer's 2011 Equity Incentive Plan, as amended. The remaining RSUs under this grant will vest as follows: (i) 35,000 RSUs vest in the first open window following the Company's 2020 Annual Meeting of Stockholders, (ii) 35,000 RSUs vest in the first open window following the Company's 2021 Annual Meeting of Stockholders and (iii) 17,500 RSUs vest in the first open window following the Company's 2022 Annual Meeting of Stockholders. Read SEC document
August 13, 2019 Filed Aug 15, 2019 16:25 UTC	BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876	Exercise / conversionCommon Stock	21,144	$0.00	$0.00	Disclosure SEC source: 0001103021-19-000006 · wf-form4_156590070881930.xml · nonDerivative · entry 1 Greenleaf Peter · CIK 0001363683 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,788 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units ("RSUs") granted to the Reporting Person on August 1, 2018 under the Issuer's 2011 Equity Incentive Plan, as amended. The remaining RSUs under this grant will vest as follows: (i) 35,000 RSUs vest in the first open window following the Company's 2020 Annual Meeting of Stockholders, (ii) 35,000 RSUs vest in the first open window following the Company's 2021 Annual Meeting of Stockholders and (iii) 17,500 RSUs vest in the first open window following the Company's 2022 Annual Meeting of Stockholders. Read SEC document
August 07, 2019 Filed Oct 3, 2019 20:40 UTC	Avalo Therapeutics, Inc. CERC · Entity 4936	GrantStock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $2.93	$0.00	Disclosure SEC source: 0001578563-19-000029 · primary_doc.xml · derivative · entry 2 Greenleaf Peter · CIK 0001363683 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-08-07 F1 · derivative.exercise_date: The stock option will vest in full on August 7, 2020, subject to the Reporting Person's continued service on such vesting date. Read SEC document
June 13, 2019 Filed Jun 14, 2019 17:49 UTC	ANTARES PHARMA, INC. ATRS · Entity 126887	GrantStock Option (right to buy) · Derivative	46,729	$0.00 Strike: $2.92	$0.00	Disclosure SEC source: 0001209191-19-037255 · doc4.xml · derivative · entry 2 Greenleaf Peter · CIK 0001363683 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,729 Underlying: Common Stock · 46,729 shares Expires 2029-06-13 F2 · shares: Represents grant of options to purchase shares of common stock, par value $0.01 per share, issued under the Antares Pharma, Inc. Equity Compensation Plan. F3 · derivative.exercise_date: The options vest and become exercisable one year from the grant date. Read SEC document
June 13, 2019 Filed Jun 14, 2019 17:49 UTC	ANTARES PHARMA, INC. ATRS · Entity 126887	GrantCommon Stock	23,973	$2.92	$70,001.16	Disclosure SEC source: 0001209191-19-037255 · doc4.xml · nonDerivative · entry 1 Greenleaf Peter · CIK 0001363683 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,973 F1 · shares: Represents grant of restricted stock units made under the Antares Pharma, Inc. Equity Compensation Plan. The shares vest one year from the grant date. The reporting person has elected to defer the receipt of shares until separation of service as a Director. Read SEC document
May 24, 2019 Filed May 29, 2019 20:29 UTC	Avalo Therapeutics, Inc. CERC · Entity 4936	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	500,000	$0.00 Strike: $4.24	$0.00	Disclosure SEC source: 0001578563-19-000017 · primary_doc.xml · derivative · entry 4 Greenleaf Peter · CIK 0001363683 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 500,000 shares Expires 2028-03-27 F2 · derivative.exercise_date: Pursuant to an agreement between the Reporting Person and the Issuer, the Reporting Person agreed to forfeit the stock option for good and valuable consideration. Read SEC document
May 24, 2019 Filed May 29, 2019 20:29 UTC	Avalo Therapeutics, Inc. CERC · Entity 4936	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	364,583	$0.00 Strike: $4.24	$0.00	Disclosure SEC source: 0001578563-19-000017 · primary_doc.xml · derivative · entry 3 Greenleaf Peter · CIK 0001363683 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,417 Underlying: Common Stock · 364,583 shares Expires 2028-03-27 F3 · derivative.exercise_date: Represents the forfeiture of 364,583 shares underlying the stock option. Pursuant to an agreement between the Reporting Person and the Issuer, the Reporting Person agreed to forfeit the stock option for good and valuable consideration. The 135,417 shares underlying the stock option that have vested will not be forfeited. Read SEC document
May 24, 2019 Filed May 29, 2019 20:29 UTC	Avalo Therapeutics, Inc. CERC · Entity 4936	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	325,000	$0.00 Strike: $6.22	$0.00	Disclosure SEC source: 0001578563-19-000017 · primary_doc.xml · derivative · entry 2 Greenleaf Peter · CIK 0001363683 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 325,000 shares Expires 2029-04-01 F2 · derivative.exercise_date: Pursuant to an agreement between the Reporting Person and the Issuer, the Reporting Person agreed to forfeit the stock option for good and valuable consideration. Read SEC document
May 24, 2019 Filed May 29, 2019 20:29 UTC	Avalo Therapeutics, Inc. CERC · Entity 4936	Disposition to issuerCommon Stock	300,000	$0.00	$0.00	Disclosure SEC source: 0001578563-19-000017 · primary_doc.xml · nonDerivative · entry 1 Greenleaf Peter · CIK 0001363683 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,500 F1 · shares: Pursuant to an agreement between the Reporting Person and the Issuer, the Reporting Person agreed to forfeit the restricted stock units for good and valuable consideration. Read SEC document
April 01, 2019 Filed Apr 2, 2019 23:54 UTC	Avalo Therapeutics, Inc. CERC · Entity 4936	GrantEmployee Stock Option (Right to Buy) · Derivative	325,000	$0.00 Strike: $6.22	$0.00	Disclosure SEC source: 0001578563-19-000014 · primary_doc.xml · derivative · entry 2 Greenleaf Peter · CIK 0001363683 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,000 Underlying: Common Stock · 325,000 shares Expires 2029-04-01 F1 · derivative.exercise_date: One fourth of the shares subject to the stock option will vest on the first anniversary of the date of grant, and the remaining three-fourths of the shares subject to the stock option will vest in equal monthly installments over the following 36 months. Read SEC document
February 01, 2019 Filed Feb 5, 2019 21:39 UTC	KIORA PHARMACEUTICALS INC EYEG · Entity 7940	GrantStock Option (right to buy) · Derivative	50,000	$0.00 Strike: $0.48	$0.00	Disclosure SEC source: 0001144204-19-005050 · tv512448_form4.xml · derivative · entry 1 Greenleaf Peter · CIK 0001363683 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-02-01 F1 · derivative.exercise_date: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to 100% of the shares underlying the Option on February 1, 2020. Read SEC document
December 13, 2018 Filed Dec 14, 2018 18:49 UTC	ANTARES PHARMA, INC. ATRS · Entity 126887	GrantStock Option (right to buy) · Derivative	20,000	$0.00 Strike: $3.11	$0.00	Disclosure SEC source: 0001209191-18-062812 · doc4.xml · derivative · entry 1 Greenleaf Peter · CIK 0001363683 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-12-12 F1 · shares: Represents initial grant of options, given to each director upon becoming a member of the board of directors, to purchase shares of common stock, par value of $0.01 per share, issued under the Antares Pharma, Inc. 2008 Equity Compensation Plan. F2 · derivative.exercise_date: The options vest in equal quarterly installments over three years from the date of grant. Read SEC document
August 14, 2018 Filed Aug 16, 2018 17:01 UTC	BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876	Exercise / conversionRestricted Stock Units · Derivative	3,644	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-18-022577 · doc4.xml · derivative · entry 2 Greenleaf Peter · CIK 0001363683 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,644 Underlying: Common Stock · 3,644 shares Expires 2022-08-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units ("RSUs") granted to the Reporting Person on August 1, 2018 under the Issuer's 2011 Equity Incentive Plan, as amended. The remaining RSUs under this grant will vest as follows: (i) 21,144 RSUs vest in the first open window following the Company's 2019 Annual Meeting of Stockholders, (ii) 35,000 RSUs vest in the first open window following the Company's 2020 Annual Meeting of Stockholders, (iii) 35,000 RSUs vest in the first open window following the Company's 2021 Annual Meeting of Stockholders and (iv) 17,500 RSUs vest in the first open window following the Company's 2022 Annual Meeting of Stockholders. F1 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units ("RSUs") granted to the Reporting Person on August 1, 2018 under the Issuer's 2011 Equity Incentive Plan, as amended. The remaining RSUs under this grant will vest as follows: (i) 21,144 RSUs vest in the first open window following the Company's 2019 Annual Meeting of Stockholders, (ii) 35,000 RSUs vest in the first open window following the Company's 2020 Annual Meeting of Stockholders, (iii) 35,000 RSUs vest in the first open window following the Company's 2021 Annual Meeting of Stockholders and (iv) 17,500 RSUs vest in the first open window following the Company's 2022 Annual Meeting of Stockholders. Read SEC document
August 14, 2018 Filed Aug 16, 2018 17:01 UTC	BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876	Exercise / conversionCommon Stock	3,644	$0.00	$0.00	Disclosure SEC source: 0000899243-18-022577 · doc4.xml · nonDerivative · entry 1 Greenleaf Peter · CIK 0001363683 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,644 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units ("RSUs") granted to the Reporting Person on August 1, 2018 under the Issuer's 2011 Equity Incentive Plan, as amended. The remaining RSUs under this grant will vest as follows: (i) 21,144 RSUs vest in the first open window following the Company's 2019 Annual Meeting of Stockholders, (ii) 35,000 RSUs vest in the first open window following the Company's 2020 Annual Meeting of Stockholders, (iii) 35,000 RSUs vest in the first open window following the Company's 2021 Annual Meeting of Stockholders and (iv) 17,500 RSUs vest in the first open window following the Company's 2022 Annual Meeting of Stockholders. F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units ("RSUs") granted to the Reporting Person on August 1, 2018 under the Issuer's 2011 Equity Incentive Plan, as amended. The remaining RSUs under this grant will vest as follows: (i) 21,144 RSUs vest in the first open window following the Company's 2019 Annual Meeting of Stockholders, (ii) 35,000 RSUs vest in the first open window following the Company's 2020 Annual Meeting of Stockholders, (iii) 35,000 RSUs vest in the first open window following the Company's 2021 Annual Meeting of Stockholders and (iv) 17,500 RSUs vest in the first open window following the Company's 2022 Annual Meeting of Stockholders. Read SEC document
August 01, 2018 Filed Aug 3, 2018 17:35 UTC	BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876	GrantStock Options (right to buy) · Derivative	64,164	$0.00 Strike: $2.93	$0.00	Disclosure SEC source: 0000899243-18-021409 · doc4.xml · derivative · entry 2 Greenleaf Peter · CIK 0001363683 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,164 Underlying: Common Stock · 64,164 shares Expires 2028-08-01 F2 · derivative.exercise_date: The stock options ("options") were issued to the Reporting Person on August 1, 2018, as compensation for service on the Issuer's board of directors. The options vest as follows: (i) 2,082 options vest in the first open window following the filing of the Company's quarterly 10Q for June 30, 2018, (ii) 12,082 options vest in the first open window following the Company's 2019 Annual Meeting of Stockholders, (iii) 20,000 options vest in the first open window following the Company's 2020 Annual Meeting of Stockholders, (iv) 20,000 options vest in the first open window following the Company's 2021 Annual Meeting of Stockholders and (v) 10,000 options vest in the first open window following the Company's 2022 Annual Meeting of Stockholders. Read SEC document
August 01, 2018 Filed Aug 3, 2018 17:35 UTC	BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876	GrantRestricted Stock Units · Derivative	112,288	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-18-021409 · doc4.xml · derivative · entry 1 Greenleaf Peter · CIK 0001363683 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,288 Underlying: Common Stock · 112,288 shares Expires 2022-08-01 F1 · derivative.exercise_date: The restricted stock units ("RSUs") were issued to the Reporting Person on August 1, 2018, as compensation for service on the Issuer's board of directors. The RSUs vest as follows: (i) 3,644 RSUs vest in the first open window following the filing of the Company's quarterly 10Q for June 30, 2018, (ii) 21,144 RSUs vest in the first open window following the Company's 2019 Annual Meeting of Stockholders, (iii) 35,000 RSUs vest in the first open window following the Company's 2020 Annual Meeting of Stockholders, (iv) 35,000 RSUs vest in the first open window following the Company's 2021 Annual Meeting of Stockholders and (v) 17,500 RSUs vest in the first open window following the Company's 2022 Annual Meeting of Stockholders. Read SEC document
July 27, 2018 Filed Aug 8, 2018 20:15 UTC	KIORA PHARMACEUTICALS INC EYEG · Entity 7940	GrantStock Option (right to buy) · Derivative	50,000	$0.00 Strike: $0.57	$0.00	Disclosure SEC source: 0001144204-18-042822 · tv500430_4.xml · derivative · entry 1 Greenleaf Peter · CIK 0001363683 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2028-07-27 F1 · derivative.exercise_date: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to 100% of the shares underlying the Option on July 27, 2019. Read SEC document
May 18, 2018 Filed May 21, 2018 23:10 UTC	Avalo Therapeutics, Inc. CERC · Entity 4936	PurchaseCommon Stock	12,500	$3.98	$49,750.00	Disclosure SEC source: 0001578563-18-000012 · primary_doc.xml · nonDerivative · entry 1 Greenleaf Peter · CIK 0001363683 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 412,500 F1 · price: This transaction was executed in multiple trades ranging from $3.95 to $4.00. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder full information regarding the number of shares and prices at which the transactions were effected. Read SEC document
March 27, 2018 Filed Mar 29, 2018 22:51 UTC	Avalo Therapeutics, Inc. CERC · Entity 4936	GrantEmployee Stock Option (Right to Buy) · Derivative	500,000	$0.00 Strike: $4.24	$0.00	Disclosure SEC source: 0001104659-18-021354 · a4.xml · derivative · entry 3 Greenleaf Peter · CIK 0001363683 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2028-03-27 F3 · derivative.exercise_date: The stock option will vest in full upon the Issuer's common stock closing at or above $12.50 per share for three consecutive trading days, provided the Reporting Person is then an officer of the Issuer on each such vesting date. Read SEC document
March 27, 2018 Filed Mar 29, 2018 22:51 UTC	Avalo Therapeutics, Inc. CERC · Entity 4936	GrantEmployee Stock Option (Right to Buy) · Derivative	500,000	$0.00 Strike: $4.24	$0.00	Disclosure SEC source: 0001104659-18-021354 · a4.xml · derivative · entry 2 Greenleaf Peter · CIK 0001363683 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2028-03-27 F2 · derivative.exercise_date: The stock option will vest 25% on the first anniversary of the date of grant and the remaining 75% of the shares subject to the stock option shall vest in equal monthly installments on each monthly anniversary date of the first vesting date over the following 48 months beginning on April 27, 2019, provided the Reporting Person is then an officer of the Issuer on each such vesting date. Read SEC document
March 27, 2018 Filed Mar 29, 2018 22:51 UTC	Avalo Therapeutics, Inc. CERC · Entity 4936	GrantCommon Stock	400,000	$0.00	$0.00	Disclosure SEC source: 0001104659-18-021354 · a4.xml · nonDerivative · entry 1 Greenleaf Peter · CIK 0001363683 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 F1 · shares: Represents restricted stock which vests in four equal annual installments beginning on March 27, 2019, provided the Reporting Person is then an officer of the Issuer on each such vesting date. The tax liability upon the vesting of the first annual installment shall be covered by the Issuer and the remaining tax liabilities upon the vesting of the second, third and fourth annual installments shall be covered by the Reporting Person. Read SEC document
February 13, 2018 Filed Feb 13, 2018 21:54 UTC	Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352	Disposition to issuerStock Option (right to buy) · Derivative	237,000	$6.15 Strike: $11.85	$1,457,550.00	Disclosure SEC source: 0001171843-18-001106 · formfour.xml · derivative · entry 6 Greenleaf Peter · CIK 0001363683 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 237,000 shares Expires 2027-03-02 F2 · derivative.exercise_date: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement. Read SEC document
February 13, 2018 Filed Feb 13, 2018 21:54 UTC	Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352	Disposition to issuerStock Option (right to buy) · Derivative	420,000	$4.20 Strike: $13.80	$1,764,000.00	Disclosure SEC source: 0001171843-18-001106 · formfour.xml · derivative · entry 5 Greenleaf Peter · CIK 0001363683 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 420,000 shares Expires 2026-03-02 F2 · derivative.exercise_date: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement. Read SEC document
February 13, 2018 Filed Feb 13, 2018 21:54 UTC	Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352	Disposition to issuerStock Option (right to buy) · Derivative	210,000	$3.18 Strike: $14.82	$667,800.00	Disclosure SEC source: 0001171843-18-001106 · formfour.xml · derivative · entry 4 Greenleaf Peter · CIK 0001363683 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 210,000 shares Expires 2025-03-04 F2 · derivative.exercise_date: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement. Read SEC document
February 13, 2018 Filed Feb 13, 2018 21:54 UTC	Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352	Disposition to issuerStock Option (right to buy) · Derivative	200,000	$12.10 Strike: $5.90	$2,420,000.00	Disclosure SEC source: 0001171843-18-001106 · formfour.xml · derivative · entry 3 Greenleaf Peter · CIK 0001363683 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires 2024-07-31 F2 · derivative.exercise_date: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement. Read SEC document
February 13, 2018 Filed Feb 13, 2018 21:54 UTC	Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352	Disposition to issuerStock Option (right to buy) · Derivative	600,000	$9.51 Strike: $8.49	$5,706,000.00	Disclosure SEC source: 0001171843-18-001106 · formfour.xml · derivative · entry 2 Greenleaf Peter · CIK 0001363683 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 600,000 shares Expires 2024-03-03 F2 · derivative.exercise_date: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement. Read SEC document
February 13, 2018 Filed Feb 13, 2018 21:54 UTC	Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352	Disposition to issuerCommon Stock, Class A	129,729	$18.00	$2,335,122.00	Disclosure SEC source: 0001171843-18-001106 · formfour.xml · nonDerivative · entry 1 Greenleaf Peter · CIK 0001363683 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: This common stock was purchased for $18.00 per share share in cash, subject to any required withholding of taxes and without interest, upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to that certain Agreement and Plan of Merger by and among Mallinckrodt plc, Sun Acquisition Co. and Sucampo Pharmaceuticals, Inc. dated December 23, 2017 (the "Merger Agreement"). The common stock consisted of both common stock and restricted stock units that were accelerated as a result of the Merger Agreement. Read SEC document
December 31, 2017 Filed Jan 4, 2018 22:16 UTC	Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352	GrantCommon Stock, Class A (ESPP)	171	$9.10	$1,556.10	Disclosure SEC source: 0001171843-18-000179 · formfour.xml · nonDerivative · entry 1 Greenleaf Peter · CIK 0001363683 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,792 F1 · security: The reporting person is voluntarily reporting the acquisition of common stock pursuant to the issuer's Employee Stock Purchase Plan (ESPP) for the period October 1, 2017 through December 31, 2017. This transaction is exempt under Rule 16(b)-3(c). F2 · price: In accordance with the ESPP, these shares were purchased at 85% of the July 3, 2017 closing price of the issuer's common stock. Read SEC document
September 30, 2017 Filed Oct 5, 2017 20:32 UTC	Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352	GrantCommon Stock, Class A (ESPP)	659	$9.10	$5,996.90	Disclosure SEC source: 0001171843-17-005956 · formfour.xml · nonDerivative · entry 1 Greenleaf Peter · CIK 0001363683 · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,621 F1 · security: The reporting person is voluntarily reporting the acquisition of common stock pursuant to the issuer's Employee Stock Purchase Plan (ESPP) for the period July 1, 2017 through September 30, 2017. This transaction is exempt under Rule 16(b)-3(c). F2 · price: In accordance with the ESPP, these shares were purchased at 85% of the July 3, 2017 closing price of the issuer's common stock. Read SEC document
June 30, 2017 Filed Jul 7, 2017 20:45 UTC	Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352	GrantCommon Stock, Class A (ESPP)	673	$8.93	$6,009.89	Disclosure SEC source: 0001171843-17-004003 · formfour.xml · nonDerivative · entry 1 Greenleaf Peter · CIK 0001363683 · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,962 F1 · security: The reporting person is voluntarily reporting the acquisition of common stock pursuant to the issuer's Employee Stock Purchase Plan (ESPP) for the period April 1, 2017 through June 30, 2017. This transaction is exempt under Rule 16(b)-3(c). F2 · price: In accordance with the ESPP, these shares were purchased at 85% of the June 30, 2017 closing price of the issuer's common stock. Read SEC document
June 30, 2017 Filed Jul 31, 2017 17:36 UTC	Avalo Therapeutics, Inc. CERC · Entity 4936	GrantEmployee Stock Option (Right to Buy) · Derivative	8,357	$0.00 Strike: $0.57	$0.00	Disclosure SEC source: 0001562180-17-002532 · primarydocument.xml · derivative · entry 1 Greenleaf Peter · CIK 0001363683 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,357 Underlying: Common Stock · 8,357 shares Expires 2027-06-29 F1 · derivative.exercise_date: The stock options will vest in full on June 30, 2018, subject to the grantees continued service on such vesting date. Read SEC document
May 12, 2017 Filed May 16, 2017 23:04 UTC	Avalo Therapeutics, Inc. CERC · Entity 4936	GrantStock Option (Right to Buy) · Derivative	16,714	$0.00 Strike: $0.80	$0.00	Disclosure SEC source: 0001209191-17-032881 · doc4.xml · derivative · entry 1 Greenleaf Peter · CIK 0001363683 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,714 Underlying: Common Stock · 16,714 shares Expires 2027-05-11 F1 · derivative.exercise_date: The stock option will vest in three substantially equal annual installments on May 11, 2018, 2019 and 2020, subject to the Reporting Person's continued service on each such vesting date. Read SEC document
March 31, 2017 Filed May 10, 2017 20:02 UTC	Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352	GrantCommon Stock, Class A (ESPP)	641	$9.35	$5,993.35	Disclosure SEC source: 0001171843-17-002919 · formfour.xml · nonDerivative · entry 1 Greenleaf Peter · CIK 0001363683 · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,289 F1 · security: The reporting person is voluntarily reporting the acquisition of common stock pursuant to the issuer's Employee Stock Purchase Plan (ESPP) for the period January 1, 2017 through March 31, 2017. This transaction is exempt under Rule 16(b)-3(c). F2 · price: In accordance with the ESPP, these shares were purchased at 85% of the March 31, 2017 closing price of the issuer's common stock. Read SEC document
March 06, 2017 Filed Mar 8, 2017 22:02 UTC	Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352	GrantEmployee Stock Option (right to buy) · Derivative	237,000	$0.00 Strike: $11.85	$0.00	Disclosure SEC source: 0001171843-17-001362 · f4_greenleaf030817.xml · derivative · entry 2 Greenleaf Peter · CIK 0001363683 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,667,000 Underlying: Class A Common Stock · 237,000 shares Expires 2027-03-02 F2 · derivative.exercise_date: The option will vest over a four-year period, with 25% vesting on March 2, 2018, and the remaining 75% vesting in equal monthly increments over the three-year period thereafter. Read SEC document
March 06, 2017 Filed Mar 8, 2017 22:02 UTC	Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352	GrantCommon stock	125,000	$0.00	$0.00	Disclosure SEC source: 0001171843-17-001362 · f4_greenleaf030817.xml · nonDerivative · entry 1 Greenleaf Peter · CIK 0001363683 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 F1 · security: Common stock granted consists of restricted stock units that vest on March 2, 2020. Read SEC document
January 20, 2017 Filed Jan 23, 2017 22:23 UTC	Savara Inc MSTX · Entity 4900	GrantRestricted Stock Units · Derivative	45,535	$0.00	$0.00	Disclosure SEC source: 0001209191-17-005145 · doc4.xml · derivative · entry 1 Greenleaf Peter · CIK 0001363683 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,535 Underlying: Common Stock · 45,535 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units vest in full upon consummation of the merger transaction contemplated by the Agreement and Plan of Merger, dated January 6, 2017, by and among the issuer, Savara Inc., and Victoria Merger Corp. (provided such event occurs on or before July 6, 2017). F2 · derivative.expiration_date: The restricted stock units vest in full upon consummation of the merger transaction contemplated by the Agreement and Plan of Merger, dated January 6, 2017, by and among the issuer, Savara Inc., and Victoria Merger Corp. (provided such event occurs on or before July 6, 2017). Read SEC document
December 31, 2016 Filed Jan 6, 2017 21:02 UTC	Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352	GrantCommon Stock, Class A (ESPP)	135	$10.46	$1,412.10	Disclosure SEC source: 0001171843-17-000124 · f4_010617greenleaf.xml · nonDerivative · entry 1 Greenleaf Peter · CIK 0001363683 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,648 F1 · security: The reporting person is voluntarily reporting the acquisition of common stock pursuant to the issuer's Employee Stock Purchase Plan (ESPP) for the period October 1, 2016 through December 31, 2016. This transaction is exempt under Rule 16(b)-3(c). F2 · price: In accordance with the ESPP, these shares were purchased at 85% of the September 30, 2016 closing price of the issuer's common stock. Read SEC document
November 29, 2016 Filed Nov 30, 2016 21:01 UTC	Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	82,459	$0.00 Strike: $6.75	$0.00	Disclosure SEC source: 0001171843-16-013441 · f4_greenleaf113016.xml · derivative · entry 6 Greenleaf Peter · CIK 0001363683 · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,430,000 Underlying: Class A Common Stock · 82,459 shares Expires 2024-09-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 29, 2016 Filed Nov 30, 2016 21:01 UTC	Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352	SaleCommon Stock, Class A	82,459	$16.75	$1,381,188.25	Disclosure SEC source: 0001171843-16-013441 · f4_greenleaf113016.xml · nonDerivative · entry 4 Greenleaf Peter · CIK 0001363683 · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,513 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.75 to $16.78, inclusive. The reporting person will, upon request, provide any security holder of Sucampo Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission full information regarding the number of shares sold at each separate price within the range. Read SEC document
November 29, 2016 Filed Nov 30, 2016 21:01 UTC	Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352	Exercise / conversionCommon Stock, Class A	82,459	$6.75	$556,598.25	Disclosure SEC source: 0001171843-16-013441 · f4_greenleaf113016.xml · nonDerivative · entry 3 Greenleaf Peter · CIK 0001363683 · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,972 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 28, 2016 Filed Nov 30, 2016 21:01 UTC	Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	117,541	$0.00 Strike: $6.75	$0.00	Disclosure SEC source: 0001171843-16-013441 · f4_greenleaf113016.xml · derivative · entry 5 Greenleaf Peter · CIK 0001363683 · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,512,459 Underlying: Class A Common Stock · 117,541 shares Expires 2024-09-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 28, 2016 Filed Nov 30, 2016 21:01 UTC	Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352	SaleCommon Stock, Class A	117,541	$16.91	$1,987,618.31	Disclosure SEC source: 0001171843-16-013441 · f4_greenleaf113016.xml · nonDerivative · entry 2 Greenleaf Peter · CIK 0001363683 · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,513 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.80 to $17.35, inclusive. The reporting person will, upon request, provide any security holder of Sucampo Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission full information regarding the number of shares sold at each separate price within the range. Read SEC document
November 28, 2016 Filed Nov 30, 2016 21:01 UTC	Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352	Exercise / conversionCommon Stock, Class A	117,541	$6.75	$793,401.75	Disclosure SEC source: 0001171843-16-013441 · f4_greenleaf113016.xml · nonDerivative · entry 1 Greenleaf Peter · CIK 0001363683 · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,054 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
September 30, 2016 Filed Oct 21, 2016 20:06 UTC	Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352	GrantCommon Stock, Class A (ESPP)	640	$9.38	$6,003.20	Disclosure SEC source: 0001171843-16-012575 · f4_greenleaf102116.xml · nonDerivative · entry 1 Greenleaf Peter · CIK 0001363683 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,513 F1 · security: The reporting person is voluntarily reporting the acquisition of common stock pursuant to the issuer's Employee Stock Purchase Plan (ESPP) for the period July 1, 2016 through September 30, 2016. This transaction is exempt under Rule 16(b)-3(c). F2 · price: In accordance with the ESPP, these shares were purchased at 85% of the July 1, 2016 closing price of the issuer's common stock. Read SEC document
June 29, 2016 Filed Sep 6, 2016 22:27 UTC	SYNLOGIC, INC. MIRN · Entity 7801	GrantStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $4.74	$0.00	Disclosure SEC source: 0001140361-16-078995 · doc1.xml · derivative · entry 1 Greenleaf Peter · CIK 0001363683 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2026-06-29 F1 · derivative.exercise_date: The option vests and become exercisable in full on the earlier of (A) June 29, 2017 or (B) immediately prior to the next annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.